Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gisle Langslet

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 19, 2023
High levels of lipoprotein(a) - assessment and treatmentTone Svilaas, Tor Ole Klemsdal, Martin Prøven Bogsrud, et al.
Scandinavian Cardiovascular Journal : SCJ|January 11, 2013
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathyMartin Prøven Bogsrud, Gisle Langslet, Leiv Ose, et al.
Atherosclerosis|October 9, 2018
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY programMichel Farnier, G Kees Hovingh, Gisle Langslet, et al.
Atherosclerosis|September 19, 2016
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE IEli M Roth, Patrick M Moriarty, Jean Bergeron, et al.
Journal of Clinical Lipidology|December 29, 2018
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trialRobert Dufour, G Kees Hovingh, John R Guyton, et al.
Journal of Clinical Lipidology|October 6, 2018
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, John R Guyton, Gisle Langslet, et al.
Cardiovascular Drugs and Therapy|May 21, 2014
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studiesJohn J P Kastelein, Jennifer G Robinson, Michel Farnier, et al.
Atherosclerosis Plus|July 19, 2024
Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinicAnja K Johansen, Martin P Bogsrud, Magne Thoresen, et al.
Atherosclerosis Plus|March 13, 2023
Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-upAnja K Johansen, Martin P Bogsrud, Jacob J Christensen, et al.
Frontiers in Pharmacology|March 19, 2021
Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective StudyKjell-Erik Arnesen, Ann Vinh Phung, Karoline Randsborg, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 19, 2023
High levels of lipoprotein(a) - assessment and treatmentTone Svilaas, Tor Ole Klemsdal, Martin Prøven Bogsrud, et al.
Scandinavian Cardiovascular Journal : SCJ|January 11, 2013
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathyMartin Prøven Bogsrud, Gisle Langslet, Leiv Ose, et al.
Atherosclerosis|October 9, 2018
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY programMichel Farnier, G Kees Hovingh, Gisle Langslet, et al.
Atherosclerosis|September 19, 2016
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE IEli M Roth, Patrick M Moriarty, Jean Bergeron, et al.
Journal of Clinical Lipidology|December 29, 2018
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trialRobert Dufour, G Kees Hovingh, John R Guyton, et al.
Journal of Clinical Lipidology|October 6, 2018
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, John R Guyton, Gisle Langslet, et al.
Cardiovascular Drugs and Therapy|May 21, 2014
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studiesJohn J P Kastelein, Jennifer G Robinson, Michel Farnier, et al.
Atherosclerosis Plus|July 19, 2024
Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinicAnja K Johansen, Martin P Bogsrud, Magne Thoresen, et al.
Atherosclerosis Plus|March 13, 2023
Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-upAnja K Johansen, Martin P Bogsrud, Jacob J Christensen, et al.
Frontiers in Pharmacology|March 19, 2021
Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective StudyKjell-Erik Arnesen, Ann Vinh Phung, Karoline Randsborg, et al.
Pageof 6